A vaccine covering different MCPyV-specific T-cell epitopes and HLA types should be used, since monotherapy with adoptive T-cell transfer of CD8+ T-cells restricted to one HLA molecule showed tumour evasion by down-regulation of that HLA molecule due to selection pressure [138]. The gene discussed is CD8A; the disease is neoplasm.